Therapy in gastric cancer. From an oncological perspective

摘要: In two randomized trials it was demonstrated that preoperative and postoperative chemotherapy shows a statistically significant clinically relevant improvement in progression-free overall survival for adenocarcinoma of the esophagogastric junction stomach when compared with surgical control arm. The absolute benefit 13% 14% after 5 years. This is clearly shown patients locally advanced tumors but remains debatable early disease stages. Postoperative mortality complication rate were not increased. Based on published study results perioperative has to be regarded as new standard care at least staged uT3/uT4 defined by endoscopic ultrasound. To date there are no indications adjuvant or chemoradiation R0 resection adequate surgery.